Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2010

Open Access 01-10-2010 | Research article

17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2

Authors: Alissa H Brandes, Christopher S Ward, Sabrina M Ronen

Published in: Breast Cancer Research | Issue 5/2010

Login to get access

Abstract

Introduction

17-allyamino-17-demethoxygeldanamycin (17-AAG), a small molecule inhibitor of Hsp90, is currently in clinical trials in breast cancer. However, 17-AAG treatment often results in inhibition of tumor growth rather than shrinkage, making detection of response a challenge. Magnetic resonance spectroscopy (MRS) and spectroscopic imaging (MRSI) are noninvasive imaging methods than can be used to monitor metabolic biomarkers of drug-target modulation. This study set out to examine the MRS-detectable metabolic consequences of Hsp90 inhibition in a breast cancer model.

Methods

MCF-7 breast cancer cells were investigated, and MRS studies were performed both on live cells and on cell extracts. 31P and 1H MRS were used to determine total cellular metabolite concentrations and 13C MRS was used to probe the metabolism of [1,2-13C]-choline. To explain the MRS metabolic findings, microarray and RT-PCR were used to analyze gene expression, and in vitro activity assays were performed to determine changes in enzymatic activity following 17-AAG treatment.

Results

Treatment of MCF-7 cells with 17-AAG for 48 hours caused a significant increase in intracellular levels of choline (to 266 ± 18% of control, P = 0.05) and phosphocholine (PC; to 181 ± 10% of control, P = 0.001) associated with an increase in expression of choline transporter SLC44A1 and an elevation in the de novo synthesis of PC. We also detected an increase in intracellular levels of glycerophosphocholine (GPC; to 176 ± 38% of control, P = 0.03) associated with an increase in PLA2 expression and activity.

Conclusions

This study determined that in the MCF-7 breast cancer model inhibition of Hsp90 by 17-AAG results in a significant MRS-detectable increase in choline, PC and GPC, which is likely due to an increase in choline transport into the cell and phospholipase activation. 1H MRSI can be used in the clinical setting to detect levels of total choline-containing metabolite (t-Cho, composed of intracellular choline, PC and GPC). As Hsp90 inhibitors enter routine clinical use, t-Cho could thus provide an easily detectable, noninvasive metabolic biomarker of Hsp90 inhibition in breast cancer patients.
Appendix
Available only for authorised users
Literature
1.
Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9: 550-562. 10.1038/nrc2664.CrossRefPubMed
2.
Solit DB, Rosen N: Hsp90: a novel target for cancer therapy. Curr Top Med Chem. 2006, 6: 1205-1214. 10.2174/156802606777812068.CrossRefPubMed
3.
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67: 2932-2937. 10.1158/0008-5472.CAN-06-4511.CrossRefPubMed
4.
Banerji U: Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009, 15: 9-14. 10.1158/1078-0432.CCR-08-0132.CrossRefPubMed
5.
Gimenez Ortiz A, Montalar Salcedo J: Heat shock proteins as targets in oncology. Clin Transl Oncol. 2010, 12: 166-173. 10.1007/s12094-010-0486-8.CrossRefPubMed
6.
Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A, Lopez-Rios F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M: Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther. 2008, 7: 3275-3284. 10.1158/1535-7163.MCT-08-0508.CrossRefPubMed
7.
Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O: Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007, 6: 1123-1132. 10.1158/1535-7163.MCT-06-0628.CrossRefPubMed
8.
Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P: Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res. 2005, 11: 7023-7032. 10.1158/1078-0432.CCR-05-0518.CrossRefPubMed
9.
Beckonert O, Monnerjahn J, Bonk U, Leibfritz D: Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed. 2003, 16: 1-11. 10.1002/nbm.797.CrossRefPubMed
10.
Glunde K, Jie C, Bhujwalla ZM: Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 64: 4270-4276. 10.1158/0008-5472.CAN-03-3829.CrossRefPubMed
11.
Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004, 64: 6732-6739. 10.1158/0008-5472.CAN-04-0489.
12.
Glunde K, Jacobs MA, Pathak AP, Artemov D, Bhujwalla ZM: Molecular and functional imaging of breast cancer. NMR Biomed. 2009, 22: 92-103. 10.1002/nbm.1269.CrossRefPubMed
13.
Ting YL, Sherr D, Degani H: Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res. 1996, 16: 1381-1388.PubMed
14.
15.
Aboagye EO, Bhujwalla ZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59: 80-84.PubMed
16.
Eliyahu G, Kreizman T, Degani H: Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int J Cancer. 2007, 120: 1721-1730. 10.1002/ijc.22293.CrossRefPubMed
17.
Bhujwalla ZM: Molecular and functional imaging of cancer. Conf Proc IEEE Eng Med Biol Soc. 2009, 47-49.
18.
Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO: Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br J Cancer. 2010, 102: 1-7. 10.1038/sj.bjc.6605457.CrossRefPubMed
19.
Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ: Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res. 2004, 10: 6661-6668. 10.1158/1078-0432.CCR-04-0039.CrossRefPubMed
20.
Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ: Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed. 2005, 18: 430-439. 10.1002/nbm.977.CrossRefPubMed
21.
Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM: Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005, 65: 3356-3363.PubMed
22.
Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006, 66: 427-434. 10.1158/0008-5472.CAN-05-1338.CrossRefPubMed
23.
Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM: Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol Cancer Ther. 2006, 5: 187-196. 10.1158/1535-7163.MCT-03-0220.CrossRefPubMed
24.
Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ: Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009, 15: 3442-3450. 10.1158/1078-0432.CCR-08-3291.CrossRefPubMed
25.
Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM: Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010, 70: 1296-1305. 10.1158/0008-5472.CAN-09-2251.CrossRefPubMedPubMedCentral
26.
Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM: Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther. 2008, 7: 2556-2565. 10.1158/1535-7163.MCT-08-0015.CrossRefPubMedPubMedCentral
27.
Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, Koutcher JA: Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res. 2005, 11: 3503-3513. 10.1158/1078-0432.CCR-04-1399.CrossRefPubMed
28.
Glunde K, Jie C, Bhujwalla ZM: Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006, 8: 758-771. 10.1593/neo.06187.CrossRefPubMedPubMedCentral
29.
Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM: Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst. 2003, 95: 1624-1633.CrossRefPubMed
30.
Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langstrom B, Bergstrom M: Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nucl Med Biol. 2009, 36: 335-342. 10.1016/j.nucmedbio.2008.12.009.CrossRefPubMed
31.
Delikatny E, Roman S, Hancock R, Jeitner T, Lander C, Rideout D, Mountford C: Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int J Cancer. 1996, 67: 72-79. 10.1002/(SICI)1097-0215(19960703)67:1<72::AID-IJC13>3.0.CO;2-E.CrossRefPubMed
32.
Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle J, Samid D, Poptani H, Glickson J, Delikatny E: Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta. 2005, 1734: 1-12.CrossRefPubMed
33.
Liimatainen T, Erkkila A, Valonen P, Vidgren H, Lakso M, Wong G, Grohn O, Yla-Herttuala S, Hakumaki J: 1H MR spectroscopic imaging of phospholipase-mediated membrane lipid release in apoptotic rat glioma in vivo. Magn Reson Med. 2008, 59: 1232-1238. 10.1002/mrm.21607.CrossRefPubMed
34.
Koepsell H, Endou H: The SLC22 drug transporter family. Pflugers Arch. 2004, 447: 666-676. 10.1007/s00424-003-1089-9.CrossRefPubMed
35.
Koepsell H, Schmitt BM, Gorboulev V: Organic cation transporters. Rev Physiol Biochem Pharmacol. 2003, 150: 36-90. full_text.PubMed
36.
Sundler R, Akesson B: Regulation of phospholipid biosynthesis in isolated rat hepatocytes. Effect of different substrates. J Biol Chem. 1975, 250: 3359-3367.PubMed
37.
Ronen SM, Rushkin E, Degani H: Lipid metabolism in T47D human breast cancer cells: 31P and 13C-NMR studies of choline and ethanolamine uptake. Biochim Biophys Acta. 1991, 1095: 5-16. 10.1016/0167-4889(91)90038-Y.CrossRefPubMed
38.
Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, Titley J, Cunningham DC, Griffiths JR, Leach MO, Clarke PA: Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer. 1999, 80: 1035-1041. 10.1038/sj.bjc.6690459.CrossRefPubMedPubMedCentral
39.
Tyagi RK, Azrad A, Degani H, Salomon Y: Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med. 1996, 35: 194-200. 10.1002/mrm.1910350210.CrossRefPubMed
40.
Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65: 9369-9376. 10.1158/0008-5472.CAN-05-1146.CrossRefPubMed
41.
Vance DE, Pelech SD, Choy PC: CTP: phosphocholine cytidylyltransferase from rat liver. Methods Enzymol. 1981, 71 (C): 576-581. full_text.CrossRefPubMed
42.
Savendahl L, Mar MH, Underwood LE, Zeisel SH: Prolonged fasting in humans results in diminished plasma choline concentrations but does not cause liver dysfunction. Am J Clin Nutr. 1997, 66: 622-625.PubMed
43.
Zeisel SH, Growdon JH, Wurtman RJ, Magil SG, Logue M: Normal plasma choline responses to ingested lecithin. Neurology. 1980, 30: 1226-1229.CrossRefPubMed
44.
Michel V, Yuan Z, Ramsubir S, Bakovic M: Choline transport for phospholipid synthesis. Exp Biol Med (Maywood). 2006, 231: 490-504.
45.
Blusztajn JK, Wurtman RJ: Choline and cholinergic neurons. Science. 1983, 221: 614-620. 10.1126/science.6867732.CrossRefPubMed
46.
Wille S, Szekeres A, Majdic O, Prager E, Staffler G, Stockl J, Kunthalert D, Prieschl EE, Baumruker T, Burtscher H, Zlabinger GJ, Knapp W, Stockinger H: Characterization of CDw92 as a member of the choline transporter-like protein family regulated specifically on dendritic cells. J Immunol. 2001, 167: 5795-5804.CrossRefPubMed
47.
Machova E, O'Regan S, Newcombe J, Meunier FM, Prentice J, Dove R, Lisa V, Dolezal V: Detection of choline transporter-like 1 protein CTL1 in neuroblastoma x glioma cells and in the CNS, and its role in choline uptake. J Neurochem. 2009, 110: 1297-1309. 10.1111/j.1471-4159.2009.06218.x.CrossRefPubMed
48.
Michel V, Bakovic M: The solute carrier 44A1 is a mitochondrial protein and mediates choline transport. FASEB J. 2009, 23: 2749-2758. 10.1096/fj.08-121491.CrossRefPubMed
49.
Katz-Brull R, Degani H: Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996, 16: 1375-1380.PubMed
50.
51.
Fullerton MD, Wagner L, Yuan Z, Bakovic M: Impaired trafficking of choline transporter-like protein-1 at plasma membrane and inhibition of choline transport in THP-1 monocyte-derived macrophages. Am J Physiol Cell Physiol. 2006, 290: C1230-1238. 10.1152/ajpcell.00255.2005.CrossRefPubMed
52.
Yuan Z, Tie A, Tarnopolsky M, Bakovic M: Genomic organization, promoter activity, and expression of the human choline transporter-like protein 1. Physiol Genomics. 2006, 26: 76-90. 10.1152/physiolgenomics.00107.2005.CrossRefPubMed
53.
Wang SA, Chuang JY, Yeh SH, Wang YT, Liu YW, Chang WC, Hung JJ: Heat shock protein 90 is important for Sp1 stability during mitosis. J Mol Biol. 2009, 387: 1106-1119. 10.1016/j.jmb.2009.02.040.CrossRefPubMed
54.
Nakamura T, Fujiwara R, Ishiguro N, Oyabu M, Nakanishi T, Shirasaka Y, Maeda T, Tamai I: Involvement of choline transporter-like proteins, CTL1 and CTL2, in glucocorticoid-induced acceleration of phosphatidylcholine synthesis via increased choline uptake. Biol Pharm Bull. 2010, 33: 691-696. 10.1248/bpb.33.691.CrossRefPubMed
55.
Kang KI, Meng X, Devin-Leclerc J, Bouhouche I, Chadli A, Cadepond F, Baulieu EE, Catelli MG: The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticosteroid-dependent promoter. Proc Natl Acad Sci USA. 1999, 96: 1439-1444. 10.1073/pnas.96.4.1439.CrossRefPubMedPubMedCentral
56.
Jackowski S, Fagone P: CTP: Phosphocholine cytidylyltransferase: paving the way from gene to membrane. J Biol Chem. 2005, 280: 853-856. 10.1074/jbc.R400031200.CrossRefPubMed
57.
Le HC, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher JA: Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r. Magn Reson Med. 2009, 62: 1112-1119. 10.1002/mrm.22137.CrossRefPubMedPubMedCentral
58.
Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO: Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer. 2002, 87: 783-789. 10.1038/sj.bjc.6600558.CrossRefPubMedPubMedCentral
59.
Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M: HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?. Anticancer Agents Med Chem. 2008, 8: 488-496.CrossRefPubMed
60.
Dean-Colomb W, Esteva FJ: Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008, 35: S31-38. 10.1053/j.seminoncol.2008.02.008. quiz S40CrossRefPubMed
61.
Powers MV, Workman P: Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006, 13 (1): S125-135. 10.1677/erc.1.01324.CrossRefPubMed
62.
Sinha S, Sinha U: Recent advances in breast MRI and MRS. NMR Biomed. 2009, 22: 3-16. 10.1002/nbm.1270.CrossRefPubMed
63.
Bolan PJ, Nelson MT, Yee D, Garwood M: Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res. 2005, 7: 149-152. 10.1186/bcr1202.CrossRefPubMedPubMedCentral
Metadata
Title
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2
Authors
Alissa H Brandes
Christopher S Ward
Sabrina M Ronen
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2729

Other articles of this Issue 5/2010

Breast Cancer Research 5/2010 Go to the issue

Research article

Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Research article

Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy

Research article

Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study

Review

Role of miR-10b in breast cancer metastasis

Research article

Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models

Meeting report

Methods in Mammary Gland Development and Cancer: the second ENDBC meeting - intravital imaging, genomics, modeling and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits